1.71
price down icon2.29%   -0.04
after-market 시간 외 거래: 1.67 -0.04 -2.34%
loading

Palisade Bio Inc 주식(PALI)의 최신 뉴스

pulisher
Dec 20, 2024

Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World

Dec 20, 2024
pulisher
Dec 17, 2024

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider

Dec 17, 2024
pulisher
Dec 17, 2024

Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz

Dec 17, 2024
pulisher
Dec 17, 2024

Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan

Dec 17, 2024
pulisher
Dec 14, 2024

PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan

Dec 14, 2024
pulisher
Dec 13, 2024

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire

Dec 13, 2024
pulisher
Dec 13, 2024

Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan

Dec 13, 2024
pulisher
Dec 12, 2024

What's Going On With Palisade Bio Stock On Thursday? - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 12, 2024
pulisher
Dec 03, 2024

PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan

Dec 03, 2024
pulisher
Dec 02, 2024

Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 25, 2024

Brookline Capital Management Estimates Palisade Bio FY2024 Earnings - Defense World

Nov 25, 2024
pulisher
Nov 21, 2024

Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire

Nov 21, 2024
pulisher
Nov 21, 2024

Palisade Bio's PALI-2108 Shows Promise in Preclinical IBD Treatment Study | PALI Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times

Nov 14, 2024
pulisher
Nov 13, 2024

Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com

Oct 30, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com

Oct 24, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News

Oct 24, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire

Oct 15, 2024
pulisher
Oct 12, 2024

Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Palisade Bio receives Health Canada nod for UC drug trial - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance

Oct 10, 2024
pulisher
Oct 08, 2024

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 08, 2024
pulisher
Oct 04, 2024

Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews

Oct 04, 2024
pulisher
Sep 28, 2024

Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed By Investing.com - Investing.com Canada

Sep 28, 2024
pulisher
Sep 28, 2024

Palisade Bio inks new deal with CEO Finley; terms disclosed - Investing.com India

Sep 28, 2024
$69.91
price up icon 0.10%
$19.00
price up icon 1.77%
$40.27
price up icon 1.72%
$360.87
price down icon 0.76%
$181.62
price up icon 2.21%
$114.13
price up icon 0.55%
자본화:     |  볼륨(24시간):